{"title":"Erhöhtes Risiko für IOD-Anstieg unter Ranibizumab und Bevacizumab im Vergleich zu Aflibercept","authors":"","doi":"10.1055/a-2123-3137","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":253432,"journal":{"name":"Klinische Monatsblätter für Augenheilkunde","volume":"55 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinische Monatsblätter für Augenheilkunde","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2123-3137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
